ReviewInternational journal of surgery case reports2025
Use of repository corticotropin injection for the prophylaxis of corneal graft rejection in high-risk patients: A case series.
Review in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Graft rejection is the leading cause of corneal allograft failure. Prompt recognition followed by aggressive steroid therapy are key elements in the treatment of graft rejection; however, prolonged corticosteroid use carries an unfavorable safety profile. Repository corticotropin injection (RCI) is United States Food and Drug Administration (FDA)-approved for the treatment of several inflammatory disease states and is indicated for use in severe ophthalmic acute and chronic allergic and inflammatory processes. In this consecutive, observational case report we provide descriptive results of the use of RCI as prophylaxis for corneal graft rejection in high-risk patients. Presentation of cases: Eligible high-risk patients were administered 80 units of RCI subcutaneously twice weekly beginning one-month pretransplant. Preoperative visual acuity (VA) and postoperative intraocular pressure, graft integrity, and VA values were collected for all patients. Discussion: The majority of patients (87.5 %) receiving RCI demonstrated maintenance or improvement of VA post-keratoplasty as well as post-operative intraocular pressures that fell within the normal range. Upon postoperative examination, the majority of patients (6/8; 75 %) treated with RCI maintained a clear graft quality with no signs of rejection. No treatment-emergent adverse effects were reported by the patients during treatment with RCI. Conclusion: The use of RCI prophylactically in high-risk, post-keratoplasty patients demonstrated maintenance or improvement in VA in the majority of patients. The results of this study also showed that RCI was safe and well tolerated, which is consistent with the known safety profile of RCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.